Publisher： Adis International
ISSN： 1172-0360
Source： Drugs & Therapy Perspectives, Vol.26, Iss.8, 2010-08, pp. : 5-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Oral saxagliptin, a potent, selective dipeptidyl peptidase-4 inhibitor, is a valuable option to improve glycaemic control in patients with type 2 diabetes mellitus. Saxagliptin as add-on therapy to monotherapy with metformin, a sulphonylurea or a thiazolidinedione improves glycaemic control and is generally well tolerated in adult patients with type 2 diabetes who have inadequate glycaemic control with their existing therapy. Adapted from Drugs 2009; 69 (15): 2103-14.[1]
Related content
Access to resources
Recommend
Liraglutide: a guide to its use in type 2 diabetes mellitus
Drugs & Therapy Perspectives, Vol. 26, Iss. 9, 2010-09 ,pp. :
Sitagliptin: a guide to its use in type 2 diabetes mellitus
Drugs & Therapy Perspectives, Vol. 23, Iss. 6, 2007-06 ,pp. :